Expected Moves

Expected regulatory and clinical progress update for the Lyme disease vaccine.

High probability of a capital raise or debt restructuring to extend operational runway.

Top-line Phase 3 data for the Lyme disease vaccine candidate VLA15, partnered with Pfizer, is a pivotal binary event for Valneva. A positive dataset that supports regulatory filings and commercial potential could quickly re-rate the stock from $6.26 toward $9.80 as investors price in milestone payments and long-duration royalty streams, while a disappointing or inconclusive outcome would likely de-risk the program’s value and push shares down toward $9.80.

Assuming supportive Phase 3 data, Valneva and Pfizer are expected to advance the Lyme vaccine VLA15 into regulatory submission and seek dossier acceptance in the US and EU. Formal acceptance of filings and a clear review timeline could significantly de-risk commercialization and push the stock from $6.26 toward $10.50, while delays, requests for additional data, or a narrower-than-expected label could leave shares languishing closer to $6.0.

Third-quarter financial results detailing commercial strategy and cash utilization.

Full-year earnings and crucial forward-looking guidance for 2027.

First-quarter print emphasizing early 2027 execution and commercialization efforts.